electroCore, Inc. announced that gammaCore therapy will continue to be listed in the United Kingdom's National Health Service (NHS) Supply Chain catalogue for an additional two years through March 17, 2026. The listing, which commenced on June 4, 2019, was scheduled to terminate on March 18, 2024. NHS Supply Chain intends to continue to include the gammaCore device within their framework agreement, commencing March 2024 through March 2026 with an option to extend for a further 2 years.

Inclusion in this catalogue helps ensure gammaCore therapy is broadly accessible to patients across the UK who may benefit from non-invasive vagus nerve stimulation and adds increased validation to the benefits realized by patients in the UK using gammaCore therapy.